Can eribulin change the treatment algorithm in the management of breast cancer?-Reference-Cited by-同舟云学术

Can eribulin change the treatment algorithm in the management of breast cancer?

Published:2013-07 Issue:4 Volume:2 Page:339-346
ISSN:1758-1923
Container-title:Breast Cancer Management
language:en
Short-container-title:Breast Cancer Management

Author:

Mirshahidi Hamid R¹,Mirshahidi Saied²,Abraham Jame³

Affiliation:

1. Loma Linda University Cancer Center, Division of Hematology/Oncology, 11175 Campus St, CSP11015, Loma Linda, CA 92354, USA

2. Loma Linda University Cancer Center, Biospecimen Laboratory, 11175 Campus St, CSP11017, Loma Linda, CA 92354, USA

3. Section of Hematology/Oncology, Mary Babb Randolph Cancer Center, West Virginia University, Morgantown, WV 26506-9162, USA.

Abstract

SUMMARY The US FDA approved eribulin as a third-line treatment for patients with metastatic breast cancer on 15 November 2010, based on the EMBRACE study. Eribulin has modified the management and enriched therapeutic options for patients with metastatic breast cancer. It has also improved life expectancy without increasing toxicity in this group of patients. In the future, this agent may achieve additional indications for treating malignancies other than breast cancer. This article summarizes data from various eribulin studies.

Publisher

Future Medicine Ltd

Subject

Radiology Nuclear Medicine and imaging,Oncology

Link

https://www.futuremedicine.com/doi/pdf/10.2217/bmt.13.31

Reference30 articles.

1. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth

2. Induction of Morphological and Biochemical Apoptosis following Prolonged Mitotic Blockage by Halichondrin B Macrocyclic Ketone Analog E7389

3. Eribulin Induces Irreversible Mitotic Blockade: Implications of Cell-Based Pharmacodynamics forIn vivoEfficacy under Intermittent Dosing Conditions

4. Delineation of the interactions between the chemotherapeutic agent eribulin mesylate (E7389) and human CYP3A4